Prophylaxis in Hemophilia

Authors

  • Dayenne Helena Catelli Universidade Federal do Rio Grande do Sul. Porto Alegre, RS, Brasil. https://orcid.org/0000-0003-3053-9704
  • Júlia Plentz Portich Hospital de Clínicas de Porto-Alegre https://orcid.org/0000-0002-4633-2903
  • Ebellins Tabares Calvache Serviço de Hematologia Clínica, Hospital de Clínicas de Porto Alegre. Porto Alegre, RS, Brasil. https://orcid.org/0000-0003-2368-1622
  • Cristiane Seganfredo Weber Serviço de Hematologia Clínica, Hospital de Clínicas de Porto Alegre. Porto Alegre, RS, Brasil.
  • Daniel Sander Hoffmann Universidade Estadual do Rio Grande do Sul. Porto Alegre, RS, Brasil. https://orcid.org/0000-0002-9839-3986
  • Guilherme Rasia Bosi Universidade de Caxias do Sul. Porto Alegre, RS, Brasil. https://orcid.org/0000-0002-9750-9342
  • Leo Sekine Universidade Federal do Rio Grande do Sul. Porto Alegre - RS, Brasil. Serviço de Hemoterapia, Hospital de Clínicas de Porto Alegre, Porto Alegre - RS, Brasil. https://orcid.org/0000-0002-7140-4980
  • Lucia Mariano da Rocha Silla Universidade Federal do Rio Grande do Sul, Porto Alegre - RS, Brasil. Serviço de Hematologia Clínica, Hospital de Clínicas de Porto Alegre, Porto Alegre - RS, Brasil. https://orcid.org/0000-0002-3892-6525

DOI:

https://doi.org/10.22491/2357-9730.126436

Keywords:

Hemophilia A, Hemophilia B, Prophylaxis

Abstract

Hemophilia is an inherited X-linked coagulopathy defined by a deficiency or abnormality in the clotting function of factor VIII (Hemophilia A) or factor IX (Hemophilia B). Prophylaxis – the regular administration of therapeutic products to maintain hemostasis and prevent bleeding – is the mainstream of treatment. Addressing the development and scientific evidence for administrating prophylaxis is the goal of this review. Prophylaxis is the therapeutic modality of choice for people with severe hemophilia, being considered, in principle, a lifelong treatment. It should have an early onset, ideally as a primary, or at least secondary. Even lifelong tertiary prophylaxis seems to offer benefit, although further studies are still lacking. Individualized strategies should lead to an optimization of the dilemma between better joint outcomes versus involved costs.

Downloads

Download data is not yet available.

Published

2023-05-29

How to Cite

1.
Catelli DH, Plentz Portich J, Tabares Calvache E, Seganfredo Weber C, Sander Hoffmann D, Rasia Bosi G, et al. Prophylaxis in Hemophilia. Clin Biomed Res [Internet]. 2023 May 29 [cited 2025 Aug. 11];43(1). Available from: https://seer.ufrgs.br/index.php/hcpa/article/view/126436

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.